goserelin acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  

62 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
goserelin acetate / Generic mfg.
2021-005184-42: Roll-over study to allow continued access to ribociclib

Ongoing
4
137
Europe
ribociclib, Zoladex, Tamoxifeno, LEE011, Film-coated tablet, Implant, Tablet, Kisqali, Goserelin, Tamoxifeno Farmoz
Novartis Pharma AG, Novartis Pharma AG
HR+, HER2- advanced or metastatic breast cancer, advanced or metastatic breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib

Recruiting
4
137
Europe, Japan, US, RoW
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Breast Cancer
02/30
03/30
2011-001193-26: Efficacy of the Acino goserelin 3.6 mg implant that is administered twice in two months in patients with prostate cancer and examination of goserelin and hormone levels in the blood after administration of the Acino goserelin 3.6 mg implant and the Zoladex® 3.6 mg implant in a smaller subgroup of patients.

Ongoing
3
145
Europe
Goserelin 3.6 mg Implant, Zoladex 3.6 mg, Implant, Zoladex 3.6 mg
Acino Supply AG, Acino Supply AG
Locally advanced, recurrent, or metastatic carcinoma of the prostate indicated for endocrine therapy, Advanced prostate cancer, Diseases [C] - Cancer [C04]
 
 
2013-000798-59: Phase III, open-label, multi-centre study to investigate the movement, effect and safety of Zoreline 3.6 mg goserelin implant (Novalon) injected under skin, in women with confirmed endometriosis

Ongoing
3
142
Europe
Zoreline 3.6 mg goserelin, Implant in pre-filled syringe
Novalon S.A, Novalon S.A
Endometriosis, Endometriosis is a common condition where tissue that behaves like the lining of the womb (the endometrium) is found outside the womb., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
MONALEESA-7, NCT02278120 / 2014-001931-36: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Checkmark 5 year median OS data in MONALEESA-7 study for HR+, HER2- metastatic breast cancer
Dec 2020 - Dec 2020: 5 year median OS data in MONALEESA-7 study for HR+, HER2- metastatic breast cancer
Checkmark OS data from MONALEESA-7 trial in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
Nov 2020 - Nov 2020: OS data from MONALEESA-7 trial in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
Checkmark Subgroup analysis data from Monaleesa-3 and Monaleesa-7 trials for advanced breast cancer at ASCO 2020
More
Completed
3
672
Europe, Canada, US, RoW
Ribociclib, LEE011, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Novartis Pharmaceuticals
Advanced Metastatic Breast Cancer
08/17
04/23
2019-000593-32: An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.

Not yet recruiting
3
142
Europe
Zoreline, Implant in pre-filled syringe
Novalon S.A., Novalon S.A.
Prostate cancer Prostatakrebs, Prostate cancer, Diseases [C] - Cancer [C04]
 
 
NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Completed
3
141
Japan, RoW
Palbociclib, Endocrine therapy
Kyoto Breast Cancer Research Network, Pfizer
Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
12/21
12/21
NCT05110170: Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Completed
3
188
RoW
LY01005, Goserelin Acetate Sustained-Release Microspheres for Injection, ZOLADEX® 3.6 mg, Goserelin Acetate Implant 3.6 mg
Luye Pharma Group Ltd.
Breast Cancer
04/22
06/22
AMEERA-5, NCT04478266 / 2020-001824-33: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Terminated
3
1068
Europe, Canada, Japan, US, RoW
Amcenestrant-matching placebo, SAR439859, Amcenestrant, Palbociclib, Ibrance, Letrozole, Goserelin, Letrozole-matching placebo
Sanofi
Breast Cancer
06/22
05/23
NCT03137368: A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）

Enrolling by invitation
3
300
RoW
Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test, Tamoxifen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Pfizer
CYP2D6 Polymorphism
10/23
10/23
NCT03936218: Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Recruiting
3
94
RoW
Inj. Goserelin (Test) Subcutaneously, Goserelin, Inj. Zoladex (Reference) Subcutaneously, Zoladex
Eurofarma Laboratorios S.A.
Advanced Prostate Cancer
11/23
06/25
NCT03936933: Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer

Recruiting
3
68
RoW
Goserelin acetate 3.6 mg Injection, Goserelin acetate, ZOLADEX® 3.6mg Injection, Zoladex
Eurofarma Laboratorios S.A.
Breast Cancer
09/24
01/25
PCS III, NCT00223145: Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone

Active, not recruiting
3
600
Canada
Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade, Bicalutamide 50 mg, Goserelin 10.8 mg
Abdenour Nabid, AstraZeneca
Prostate Cancer
12/23
12/23
NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
PATHWAY, NCT03423199: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Active, not recruiting
3
180
Japan, RoW
Palbociclib, PD-0332991, Placebo, Tamoxifen, Goserelin
National Cancer Center, Japan, Pfizer, Korean Cancer Study Group
Breast Neoplasms
09/25
09/25
NCT05009290: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Recruiting
3
1256
RoW
SHR3680, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
10/27
10/31
ADJUVANT WIDER, NCT05827081: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Suspended
3
3100
RoW
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Novartis Pharmaceuticals
Early Breast Cancer
09/29
09/30
CARLHA-2, NCT04181203: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Recruiting
3
490
Europe
Apalutamide, ARN-509, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa), leuprolide, goserelin, triptorelin acetate
UNICANCER, Janssen Pharmaceutica
Prostate Cancer
09/28
12/33
PRIMORDIUM, NCT04557059 / 2019-002957-46: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Recruiting
3
412
Europe, US, RoW
Radiotherapy, LHRHa, Apalutamide, JNJ-56021927
Janssen Pharmaceutica N.V., Belgium
Prostatic Neoplasms
08/29
08/29
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
CTR20201637: A clinical study to evaluate the safety and preliminary efficacy of FCN-437c in the treatment of female patients with ER-positive, HER2-negative advanced breast cancer

Completed
2
60
China
FCN-437 - Fosun Pharma
Chongqing Fuchang Pharmaceutical Research Co., Ltd./Shanghai Fushang Huichuang Pharmaceutical Research Co., Ltd.
ER-positive, HER2-negative advanced breast cancer
 
 
AMBER, jRCTs051220133: JBCRG-M08( trial)

Recruiting
2
150
Japan
Verzenio (abemaciclib) - Eli Lilly, anastrozole - Generic mfg., fulvestrant - Generic mfg., letrozole - Generic mfg., goserelin acetate - Generic mfg., leuprorelin (CKD-841) - Chong Kun Dang
Osaka University Hospital, Eli Lilly Japan K.K
Hormone receptor-positive, HER2-negative inoperable or recurrent breast cancer
 
 
ASN-002-IL, NCT02107391 / 2004-002708-13 / ACTRN12619001298101: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

Completed
2
63
RoW
Dendritic Cells DCVAC/PCa, Leuprolide acetate, Lupron, Goserelin Acetate, Zoladex
SOTIO a.s., Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma, Basal Cell Nevus Syndrome (BCNS)
12/15
06/16
2017-000154-19: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer

Not yet recruiting
2
90
Europe
Alpelisib, BYL719, Tablet, Solution for injection, Implant in pre-filled syringe, Powder and solvent for solution for injection, FASLODEX, ZOLADEX, ENANTONE
UNICANCER, Novartis
PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy., Breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT03007979: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed
2
55
US
Palbociclib, Ibrance, Letrozole, Femara, Fulvestrant, Faslodex, Optional research biopsy, Goserelin, Zoladex, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Washington University School of Medicine, Pfizer
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
03/20
03/23
PETREMAC, NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the Trial

Active, not recruiting
2
200
Europe
Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone), Neoadjuvant docetaxel + cyclophosphamide, Neoadjuvant docetaxel, Neoadjuvant docetaxel + trastuzumab + pertuzumab, Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab, Neoadjuvant olaparib, Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone), Breast conserving surgery or mastectomy + SNB/axillary dissection, Postoperative radiotherapy breast/chest wall + regional lymph nodes, Adjuvant trastuzumab, Adjuvant letrozole (postmenopausal women), Adjuvant tamoxifen + goserelin (premenopausal women), Adjuvant palbociclib (if palbociclib given neoadjuvant), Adjuvant Epirubicin+ Cyclophosphamide
Haukeland University Hospital, Helse Vest, Pfizer, AstraZeneca
Breast Cancer
06/20
06/30
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
2018-003832-57: Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients.

Not yet recruiting
2
166
Europe
Durvalumab, Olaparib, Fulvestrant, Goserelin, MEDI4736, Solution for infusion, Tablet, Solution for injection, Implant in pre-filled syringe, Faslodex, ZOLADEX
UNICANCER, Laboratories AstraZeneca
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status., ER-positive and HER2-negative metastatic or locally advanced breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT01723774: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, not recruiting
2
84
US
PD0332991, Anastrozole, Arimidex®, Goserelin, Zoladex®, Decapeptide I, Surgery (standard of care), Tumor biopsy
Washington University School of Medicine, Pfizer
Breast Neoplasms
04/21
08/26
YATAGARASU, NCT04325828: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Active, not recruiting
2
31
Japan
Apalutamide, JNJ-56021927, GnRH Agonist
Janssen Pharmaceutical K.K.
Salivary Gland Neoplasms
06/21
09/25
AMALEE, NCT03822468 / 2018-004234-15: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Active, not recruiting
2
376
Europe, Canada, US, RoW
Ribociclib, LEE011, Anastrozole, Letrozole, Goserelin
Novartis Pharmaceuticals
Breast Cancer
06/21
07/24
BYLieve, NCT03056755 / 2016-004586-67: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Checkmark Presentation of data from BYLieve trial for HR+/HER2- breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from BYLieve trial for HR+/HER2- breast cancer at SABCS 2022
Checkmark Data from BYLieve study for advanced breast cancer at ASCO 2020
May 2020 - May 2020: Data from BYLieve study for advanced breast cancer at ASCO 2020
Active, not recruiting
2
379
Europe, Canada, Japan, US, RoW
Alpelisib, BYL719, Fulvestrant, Letrozole, Goserelin, Leuprolide
Novartis Pharmaceuticals
Breast Cancer
06/21
07/25
SAVE, NCT03899077 / 2018-004365-13: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Recruiting
2
202
Europe
Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant, Triptorelin Pamoate, Degarelix acetate
Cancer Research Antwerp, Janssen Pharmaceutica
Cancer of Prostate
08/25
12/25
RIGHT Choice, NCT03839823: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed
2
223
RoW
Docetaxel / Capecitabine, Combination chemotherapy group., The chemotherapy regimen will be decided by the treating physician., Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine, Ribociclib, Endocrine treatment arm:, NSAI + goserelin+ ribociclib, Letrozole OR Anastrozole, Goserelin
Novartis Pharmaceuticals
Breast Cancer
04/22
05/23
NCT03671330: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Active, not recruiting
2
327
RoW
Ribociclib Placebo, LEE011 Placebo, Ribociclib, LEE011, NSAI: Letrozole or Anastrazole, Letrozole, Goserelin
Novartis Pharmaceuticals
Breast Cancer
04/22
04/25
2022-002431-53: A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER DAROLUTAMIDE (ODM-201) CONCOMITANT A LA RADIOTHERAPIE CHEZ LES PATIENTS PRESENTANT UN CANCER DE LA PROSTATE A RISQUE INTERMEDIAIRE DEFAVORABLE : UNE ETUDE MULTICENTRIQUE RANDOMISEE NON-COMPARATIVE DE PHASE II

Ongoing
2
62
Europe
DAROLUTAMIDE, Dégarélix, Goséréline, Leuproréline, Triptoréline, RADIOTHERAPY, Tablet, Powder and solvent for solution for injection, Implant in pre-filled syringe, , NUBEQA, FIRMAGON, ZOLADEX, ELIGARD, ENANTONE, DECAPEPTYL, GONAPEPTYL, RADIOTHERAPY
Institut Bergonié, Bayer Healthcare SAS
Prostate cancer Cancer de la prostate, Intermediate unfavorable risk prostate cancer Cancer de la prostate à risque intermédiaire défavorable, Diseases [C] - Cancer [C04]
 
 
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoldaex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
CARABELA, NCT04293393: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruiting
2
200
Europe
Doxorubicin, Caelyx, Cyclophosphamide, Genoxal, Taxane, Paclitaxel, Docetaxel, Letrozole, Femara, Abemaciclib, Verzenios, LHRH Analogue, Goserelin, Leuprolide
Spanish Breast Cancer Research Group, Eli Lilly and Company
Early Breast Cancer
06/23
02/33
BTCRC-HN17-111, NCT03942653: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Recruiting
2
20
US
Goserelin Acetate, Pembrolizumab
Manish Patel, Merck Sharp & Dohme LLC
Salivary Gland Carcinoma
05/24
05/24
EORTC-1532, NCT02972060 / 2016-004334-17: ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Active, not recruiting
2
61
Europe
ODM-201, ADT
European Organisation for Research and Treatment of Cancer - EORTC, Bayer
Prostate Cancer
01/23
12/36
NEOLETRIB, NCT05163106: Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Recruiting
2
100
Europe
Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet, Femara; Kisqali, Goserelin, Zoladex
University Hospital, Akershus, Novartis, Vestre Viken Hospital Trust
Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Locally Advanced Breast Cancer, Luminal A Breast Cancer, Luminal B Breast Cancer
12/23
12/24
NePtune, NCT05498272: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations

Recruiting
2
32
US
Olaparib, Lynparza, LHRH agonist, Goserelin, Triptorelin, Leuprolide
Rana McKay, MD, AstraZeneca, University of California, San Diego
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
12/25
12/26
ImmunoADAPT, NCT03573648: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting
2
33
US
Avelumab, Bavencio, Endocrine therapy, Hormone therapy, Palbociclib, Ibrance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Pfizer, Allegheny Health Network, National Institutes of Health (NIH)
Breast Cancer
07/24
12/25
ESCALATE, NCT06225284: Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

Not yet recruiting
2
124
NA
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
National Taiwan University Hospital, Ministry of Health and Welfare, Debiopharm International SA
Triple Negative Breast Cancer, Premenopausal Breast Cancer
12/26
12/30
ROSALINE, NCT04551495 / 2019-004942-14: Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

Active, not recruiting
2
65
Europe
Entrectinib, Letrozole, Goserelin
Jules Bordet Institute, Hoffmann-La Roche
Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer
08/24
10/24
NCT04126070: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Active, not recruiting
2
60
US
Androgen Deprivation Therapy, Leuprolide, Lupron Depot, Goserelin acetate, Zoladex, Degarelix, Firmagon, Nivolumab, Docetaxel, Taxotere
Xiao X. Wei, MD, Bristol-Myers Squibb
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
06/24
06/25
DISCOVARY, NCT05694819: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma

Active, not recruiting
2
56
Japan
Darolutamide, Goserelin
National Cancer Center Hospital East, Bayer Yakuhin, Ltd.
Salivary Gland Cancer
08/24
02/26
FACILE, NCT03944434 / 2018-002514-12: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer

Active, not recruiting
2
116
Europe
Ribociclib, Kisqali, Aromatase Inhibitors, non steroideal, Femara, Arimidex, LHRH agonist, Triptorelin, Leuprolide, Goserelin
Fondazione Sandro Pitigliani, Novartis
Breast Cancer
12/24
11/25
NCT02476786: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting
2
50
US
FACT-B, Goserelin, Goserelin acetate, Zoladex, Anastrozole, Arimidex®, Exemestane, Aromasin®, Fulvestrant, Faslodex®, Tamoxifen, Nolvadex®, Archived tissue collection
Washington University School of Medicine, Genomic Health®, Inc.
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
07/25
01/30
APEX, NCT06059118: Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
50
US
DFMO, eflornithine, difluoromethylornithine, testosterone cypionate, DEPO-Testosterone Injection, Luteinizing hormone-releasing hormone (LHRH) analogue, Zoladex, Trelstar, Eligard, Lupron, Degarelix, Relugolix, Enzalutamide, Xtandi
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Panbela Therapeutics, Prostate Cancer Foundation, United States Department of Defense
Prostate Cancer
01/26
11/29
EVANGELINE, NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Recruiting
2
180
US
(Z)-endoxifen, endoxifen, exemestane, Aromasin, goserelin, Zoladex
Atossa Therapeutics, Inc., InClin
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
02/26
09/26
BOUQUET, NCT04931342 / 2020-004936-72: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruiting
2
176
Europe, Canada, US, RoW
Ipatasertib, RO5532961, Cobimetinib, RO5514041, Trastuzumab Emtansine, RO5304020, Atezolizumab, RO5541267, Tecentriq, Bevacizumab, RO4876646, Avastin, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Hoffmann-La Roche, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Ovarian Cancer
05/28
12/28
NCT05617885: Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Active, not recruiting
1/2
93
US
Darolutamide, Nubeqa, Abemaciclib, Verzenio, GNRH-A Leuprolide Acetate, Eligard, Lupron Depot, Lupron Depot-Ped, GNRH-A Goserelin, Zoladex, Degarelix, Firmagon
Praful Ravi, MB BCHir, MRCP, Eli Lilly and Company, Bayer
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
07/24
06/26
NCT02023463: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Active, not recruiting
1
25
US
Enzalutamide, Xtandi, MDV3100, Goserelin acetate, Goserelin, Zoladex, Leuprolide acetate, Leuprorelin, Leuprolide, Radiation therapy, irradiation, radiotherapy, therapy, radiation
Sidney Kimmel Cancer Center at Thomas Jefferson University, Astellas Pharma Inc, Medivation, Inc.
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
07/17
01/40
NCT02626507: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Checkmark gedatolisib plus Ibrance in ER+/HER2- metastatic breast cancer
Apr 2021 - Apr 2021: gedatolisib plus Ibrance in ER+/HER2- metastatic breast cancer
Active, not recruiting
1
18
US
Gedatolisib, Code name PF-05212384, PKI-587, Faslodex, Fulvestrant, Palbociclib, Ibrance, Zoladex, goserelin
Hoffman Oncology, DSCS CRO
Breast Cancer
02/22
03/22
GO39932, NCT03332797: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Active, not recruiting
1
181
Europe, US, RoW
GDC-9545, Giredestrant, RO7197597, RG6171, Palbociclib, LHRH Agonist
Genentech, Inc.
Breast Cancer
06/25
06/25
NCT05870579: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Recruiting
1
48
Europe
[68Ga]Ga-NeoB, gallium neoB, [177Lu]Lu-NeoB, lutetium neoB, Ribociclib, kisqali, Fulvestrant, Goserelin, zoladex
Novartis Pharmaceuticals
Breast Cancer
12/31
12/31
NCT05701007: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed
N/A
1
Europe
abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel, Radium-223, Lutetium-177, degarelix, goserelin, leuprorelin, triptorelin
Pfizer
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
04/24
04/24
NCT05184257: Zoladex® 10.8 BC RWS

Completed
N/A
1176
RoW
AstraZeneca
Breast Cancer
12/23
12/23
NCT05149131: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

Completed
N/A
960
Canada
ADT (Eligard®*) with or without treatment intensification
Bayer
Metastatic Castration-sensitive Prostate Cancer
08/22
08/22
NCT04034095: A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Active, not recruiting
N/A
979
Japan
Androgen-deprivation Therapy (ADT), Bicalutamide, Abiraterone, Prednisolone, Docetaxel, Enzalutamide, Apalutamide
Janssen Pharmaceutical K.K.
Prostatic Neoplasms
08/24
10/25
NCT05628363: Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Recruiting
N/A
25
US
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, SBRT, Androgen deprivation therapy, ADT
Washington University School of Medicine, Varian Medical Systems
Prostate Cancer, Cancer of the Prostate
04/26
01/31

Download Options